Tampa, Florida, United States – The Newswire – November 30, 2022 – CTT Pharmaceutical Holdings, Inc (OTC:CTTH) has started the development of our three new oral products. CTT is using it’s patented technology to develop chewing gum, gummies and capsules and anticipate completion of these new oral products by the end of Q4 2022. CTT will immediately start testing our new products for stability and efficacy.
Ryan Khouri, CEO of CTT Pharma stated, I’m excited to see development start and look forward to the completion of these new products. CTT will continue to update shareholders as more news becomes available.
About CTT Pharma
CTT has patents granted and pending in over 50 countries giving CTT a global reach with our fast drug delivery technology. These patents protect our dissolvable strips and many other oral products. CTT’s dissolvable strips enter the bloodstream once dissolved in the mouth bypassing the lungs and digestive tract, allowing for better absorption, faster onset, as fast as an injection, and the ability to combine APIs.
CTT successfully received Health Canada approval for our dissolvable strips and sold out our initial product in weeks. CTT can utilize its technology into many APIs such as Nicotine, CBD, Caffeine, Vitamins and Pharmaceuticals to name a few.
CTT Pharma – 813-606-0060